Immulina TM for Atrial Premature Complexes

Phase-Based Progress Estimates
University of Mississippi Medical Center, Jackson, MS
Atrial Premature Complexes+3 More
Immulina TM - DietarySupplement
All Sexes
What conditions do you have?

Study Summary

This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).

Eligible Conditions

  • Atrial Premature Complexes

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Atrial Premature Complexes

Study Objectives

3 Primary · 11 Secondary · Reporting Duration: 12 weeks

12 weeks
Cytolytic T lymphocyte (CTL) number
Natural Killer (NK) cell count
Natural Killer cell (NK)-mediated cytotoxicity
Plasma CRP (C-Reactive Protein, ng/mL)
Plasma D-Dimer, pg/mL
Plasma IL-6 (Interleukin 6, pg/mL)
SARS-CoV-2-specific antibody responses
SARS-CoV-2-specific immune responses on memory B cell levels
SARS-CoV-2-specific immune responses on memory T cell levels
serum Interferon alpha, pg/mL
serum Interferon gamma, pg/mL

Trial Safety

Safety Progress

1 of 3

Other trials for Atrial Premature Complexes

Trial Design

2 Treatment Groups

Immulina TM 800 mg/day
1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

120 Total Participants · 2 Treatment Groups

Primary Treatment: Immulina TM · Has Placebo Group · N/A

Immulina TM 800 mg/day
Experimental Group · 1 Intervention: Immulina TM · Intervention Types: DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Closest Location: University of Mississippi Medical Center · Jackson, MS
Photo of mississippi 1Photo of mississippi 2Photo of mississippi 3
2011First Recorded Clinical Trial
0 TrialsResearching Atrial Premature Complexes
517 CompletedClinical Trials

Who is running the clinical trial?

University of Mississippi Medical CenterLead Sponsor
158 Previous Clinical Trials
208,534 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
210 Previous Clinical Trials
90,797 Total Patients Enrolled
Gailen D Mashall, Jr., MD, PhDPrincipal InvestigatorUniversity of Mississippi Medical Center

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old and at least 99 years old.
You have a body temperature between 36.1°C and 37.7°C.
You are fasting for at least 2 hours prior to the blood draws.
You are able to read and write in English.
You are not participating in a clinical study, within the last 30 days.
You are willing and able to comply with all study requirements, including swallowing size 4 capsules (approximately 0.5\" long and 0.25\" diameter) and having phlebotomy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.